




(€0120



adoss® TCP is an injectable bone graft composed by 65% of β-Tricalcium Phosphate (β-TCP) and 35% of Calcium Sulfate (CS).

The biphasic composition allows a dual resorption in which the CS, acts as a barrier membrane that makes it ideal to soft tissue and other graft materials to ingress. On the second phase the β -TCP will act as a scaffold for further bone regeneration, being slowly resorbed by osteoclastic processes over a longer term, as part of the remodeling process in order to enable the formation of new mature bone.


Why choose adoss TCP?

 Resorbable
 Is replaced by new vital bone within 1-6 months.

 Biocompatible
 Has no side effects, annules the risks of diseases and graft rejection.

 Adaptability
 Can be used to fill up high variety of shapes and sizes of bone void.

 Osteocondutive
 Due to the optimized porosity and interconnected pores, the granules provide an ideal osteoconductive matrix for the formation of new bone.



SEM (scanning electron microscope) image of adoss® TCP



Histology at ten weeks

Volume Stability Due to c

Due to optimizes packing density no structural.

Indications



Traumatology - Upper and lower limps;



Spinal surgery - Cage filings; - Posterolateral fusions;



Bone cavity filing - Cysts; - Bone tumors;



Extremities - Hand and foot surgery;



Craniofacial surgéries Cranioplasty; - Granial recontouring; Cranial flap augmentation; - Skull base defect repair;



Sports Surgeries

-Knee surgery; -Elbow surgery; -Shoulder surgery;

REFERENCES	PRESENTATION	QUANTITY
ADS050530S	Syringe	3units x 0,5cc
ADS050550S		5units x 0,5cc
ADS101030S		3units x 1,0cc
ADS101050S		5units x 1,0cc



Fill with sterile saline (0.9% Sodium <u>Chloride for injection</u>) to the top of







0



MD Leventis, P. Fairbairn, et al. "Biological response to B-Tricalcium Phosphate/Calcium sulfate synthetic graft material: An experimental study", Implant Dentistry, Vol 23 (1), 37 - 43. Ω P. Fairbairn, M. D. Leventis, et al. "Implant placement with simultaneous bone grafting using a novel allaplastic particulate graft material", EAO, Rome, Italy, 25-27 september, 2014 Ω P. Fairbairn, M. D. Leventis, (2015, January) "The body wants to heal", BDIZ EDI konkret, 72 - 80. Ω P. Fairbairn, M. D. Leventis, (2015, October) "Revised protocols", the dentist, 118 - 124 Ω P. Fairbairn, M. D. Leventis, "Protocol for bone augmentation with simultaneous early implant placement: A retrospective multicenter clinical study", International Journal of Dentistry, Vol 15, 1-8.

Awards:

- National Young Entrepreneur Award 2012
 GESVENTURE Internationalization Award 2011
 Entrepreneur of the Year Award 2011
- National Women Entrepreneur Award 2011
 BES Innovation Award 2009
 Entrepreneurship Merit Medal 2009

- Business Ideas Contest Award 2008
 College of Material Science Engineering Award 2006
 Federation of the European Materials Societies Award 2003

Manufactured by:



Centro Empresarial Lusoworld II Rua Pé de Mouro, nº26 - Linhó 2710-335 Sintra, Portugal Tel: +351 211 941 737 | e-Fax: +351 211 946 681 e-mail: sales@medbone.eu www.medbone.eu



er.G1 11-2016

Distributed by: